BCR and diffuse large B-cell lymphoma: Of note, BLNK and BTK genes, key components of the BCR signaling, have been described as pivotal modulators of the sensitivity of rituximab that is contained in the standard care R-CHOP chemotherapy regimen for DLBCL [53].